Renaissance Technologies (RenTech)'s CPRX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 2.35 M shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $58.12 M, representing 0.09% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 40 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2022, adding 1.19 M shares. Largest reduction occurred in Q2 2018, reducing 1.24 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -302,600 | Reduce 11.42% | 2.35 M | $24.76 |
| Q4 2025 | -894,753 | Reduce 25.24% | 2.65 M | $23.34 |
| Q3 2025 | +293,314 | Add 9.02% | 3.54 M | $19.70 |
| Q2 2025 | +295,200 | Add 9.99% | 3.25 M | $21.70 |
| Q1 2025 | +250,200 | Add 9.25% | 2.96 M | $24.25 |
| Q4 2024 | +180,100 | Add 7.13% | 2.71 M | $20.87 |
| Q3 2024 | +350,289 | Add 16.10% | 2.53 M | $19.88 |
| Q2 2024 | +287,300 | Add 15.21% | 2.18 M | $15.49 |
| Q1 2024 | +291,000 | Add 18.22% | 1.89 M | $15.94 |
| Q4 2023 | +308,327 | Add 23.92% | 1.6 M | $16.81 |
| Q3 2023 | +134,200 | Add 11.62% | 1.29 M | $11.69 |
| Q2 2023 | +64,800 | Add 5.94% | 1.15 M | $0.01 |
| Q1 2023 | -141,412 | Reduce 11.48% | 1.09 M | $0.02 |
| Q4 2022 | -995,000 | Reduce 44.69% | 1.23 M | $0.02 |
| Q3 2022 | +1.19 M | Add 115.83% | 2.23 M | $12.83 |
| Q2 2022 | +678,500 | Add 192.15% | 1.03 M | $7.01 |
| Q1 2022 | -69,774 | Reduce 16.50% | 353,112 | $8.29 |
| Q4 2021 | +370,648 | Add 709.54% | 422,886 | $6.77 |
| Q3 2021 | +52,238 | New Buy | 52,238 | $5.30 |
| Q2 2020 | -739,226 | Sold Out | 0 | $0.00 |
| Q1 2020 | +563,526 | Add 320.73% | 739,226 | $3.85 |
| Q4 2019 | +175,700 | New Buy | 175,700 | $3.75 |
| Q4 2018 | -152,722 | Sold Out | 0 | $0.00 |
| Q3 2018 | +6,256 | Add 4.27% | 152,722 | $3.78 |
| Q2 2018 | -1.24 M | Reduce 89.46% | 146,466 | $3.12 |
| Q1 2018 | +275,400 | Add 24.72% | 1.39 M | $2.39 |
| Q4 2017 | +532,500 | Add 91.56% | 1.11 M | $3.91 |
| Q3 2017 | -310,200 | Reduce 34.78% | 581,600 | $2.52 |
| Q2 2017 | +509,400 | Add 133.21% | 891,800 | $2.76 |
| Q1 2017 | +382,400 | New Buy | 382,400 | $1.95 |
| Q4 2016 | -15,000 | Sold Out | 0 | $0.00 |
| Q3 2016 | +15,000 | New Buy | 15,000 | $1.07 |
| Q2 2016 | -175,800 | Sold Out | 0 | $0.00 |
| Q1 2016 | +175,800 | New Buy | 175,800 | $1.17 |
| Q2 2015 | -21,227 | Sold Out | 0 | $0.00 |
| Q1 2015 | +21,227 | New Buy | 21,227 | $4.33 |
| Q4 2014 | -196,500 | Sold Out | 0 | $0.00 |
| Q3 2014 | +196,500 | New Buy | 196,500 | $3.32 |
| Q4 2013 | -138,500 | Sold Out | 0 | $0.00 |
| Q3 2013 | +138,500 | New Buy | 138,500 | $3.05 |
Renaissance Technologies (RenTech)'s Catalyst Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q3 2013, acquiring 138,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Catalyst Pharmaceuticals, Inc. (CPRX) for 40 quarters since Q3 2013.
Renaissance Technologies (RenTech)'s largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q3 2022, adding 2,226,512 shares worth $28.57 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 2,347,477 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $58.12 M.
As of the Q1 2026 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.09% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 3,544,830 shares, as reported at the end of Q3 2025.